Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease

By Green Colin   Picot Joanna   Loveman Emma   Takeda Andrea   Kirby Jo   Clegg Andrew  

PharmacoEconomics, Vol. 23, Iss. 12, 2005-01 ,pp. : 1271-1282

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease: A Review with Methodological Considerations

By Wimo A.  

Drugs & Aging, Vol. 21, Iss. 5, 2004-01 ,pp. : 279-295

Adis International

Access to resources Recommend Favorite

A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer's Disease

By Kirby Joanna   Green Colin   Loveman Emma   Clegg Andrew   Picot Joanna   Takeda Andrea   Payne Elizabeth  

Drugs & Aging, Vol. 23, Iss. 3, 2006-01 ,pp. : 227-240

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease: A Markov Model in Finland

By François C.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 373-384

Adis International

Access to resources Recommend Favorite

Cholinesterase Inhibitors for Alzheimer's Disease

By Grutzendler J.   Morris J.C.  

Drugs, Vol. 61, Iss. 1, 2001-01 ,pp. : 41-52

Adis International

Access to resources Recommend Favorite